An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.

This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.

A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.

This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.

This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.

The invention provides a combination or salt of lipoic acid and a compound of formula (I): The combinations and salts are useful for treating diabetes.

The invention provides a combination or salt of lipoic acid and a compound of formula (I): The combinations and salts are useful for treating diabetes.

The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.8, M.sup.1, M.sup.2, M.sup.3, M.sup.4, M.sup.5, M.sup.6 and M.sup.7 are each independently a member selected from the group consisting of H, C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; R.sup.4, R.sup.7 and R.sup.9 are each independently selected from the group consisting of C.sub.1-6 alkoxy and OH; R.sup.10 is a member selected from the group consisting of H, —OH, —OP(O)Me.sub.2,

##STR00002##

—O—(CH.sub.2).sub.n—OH and —O—(CH.sub.2).sub.m—O—(CH.sub.2).sub.o—CH.sub.3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L.sup.1 and L.sup.4 are independently selected from the group consisting of:

##STR00003##

wherein each M.sup.8 is independently a member selected from the group consisting of C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; each of L.sup.2 and L.sup.3 are independently selected from the group consisting of:

##STR00004##

and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.

The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.8, M.sup.1, M.sup.2, M.sup.3, M.sup.4, M.sup.5, M.sup.6 and M.sup.7 are each independently a member selected from the group consisting of H, C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; R.sup.4, R.sup.7 and R.sup.9 are each independently selected from the group consisting of C.sub.1-6 alkoxy and OH; R.sup.10 is a member selected from the group consisting of H, —OH, —OP(O)Me.sub.2,

##STR00002##

—O—(CH.sub.2).sub.n—OH and —O—(CH.sub.2).sub.m—O—(CH.sub.2).sub.o—CH.sub.3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L.sup.1 and L.sup.4 are independently selected from the group consisting of:

##STR00003##

wherein each M.sup.8 is independently a member selected from the group consisting of C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; each of L.sup.2 and L.sup.3 are independently selected from the group consisting of:

##STR00004##

and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.